Surge in Life Sciences Investment in Region Continues: 2021 Total Exceeded $12 Billion

The life sciences sector in Greater Philadelphia benefited from robust investment in 2021. The 11-county area of Southeastern Pennsylvania, northern Delaware and southern New Jersey combined saw more than $12 billion invested, according to biopharma database company DealForma. The $12 billion tally included more than $3 billion for cell and gene therapy. Investment deals ranged from Series A rounds through IPOs. Among the technologies funded were biologics, cell and gene therapy, small molecules, as well as medical device and digital health, including artificial intelligence.

Reflected in the DealForma data were eight IPOs with a combined value of more than $750 million. […]

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Castle Creek Biosciences, Inc. announces research collaboration with Mayo Clinic.

Article from PR Newswire

Philadelphia’s startup ecosystem climbs 15 spots into the top 30 worldwide, report says

Philadelphia’s startup scene is ranked amongst the best-performing in the world according to Startup Genome.

Article from Philadelphia Business Journal 

Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Penn Medicine is one of 30 sites chosen by the National Institute of Health to serve as an Impact of Genomic Variation on Function investigator.

Article from Penn Medicine

September 16th, 2021|Cell and Gene Therapy, Investments, Largest Employers, Life Sciences, Regional News Roundup|Comments Off on Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Roche’s Genetech has signed a deal to partner with Adaptimmune on off-the-shelf T cell therapies.

Article from Endpoints News

September 10th, 2021|Cell and Gene Therapy, Investments, Regional News Roundup|Comments Off on Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology

Director of the University of Pennsylvania’s gene therapy program, Dr. James Wilson, has formed a company specializing in gene editing.

Article from Philadelphia Business Journal

September 9th, 2021|Cell and Gene Therapy, Innovation, Investments, Regional News Roundup|Comments Off on Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology

Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy

A new study from Penn Medicine demonstrates a naturally occurring RNA can activate the body’s own natural T cells to seek out cancer cells that may have escaped recognition by CAR T cells.

Article from Penn Medicine

September 2nd, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy

Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

Renovacor, Inc. will begin trading on the New York Stock Exchange under ticket symbols “RCOR” and “RCOR.WS”, respectively.

Article from Business Wire

September 2nd, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

A clinical-stage biopharmaceutical company has announced the completion of a new development.

Article from Business Wire

July 27th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Go to Top